Effect of intravenous ibuprofen versus intravenous paracetamol on the occlusion of patent ductus arteriosus in preterm infants: a single-blind randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N321

Enrollment

Registered

2019-12-10

Start date

2019-11-24

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent ductus arteriosus. Patent ductus arteriosus

Interventions

Intervention 1: Intervention group: Intravenous ibuprofen (manufactured by Caspian Tamin Pharmaceutical Company) first 10 mg/kg then 5 mg/kg every 12 hours for 3 days. Intervention 2: Control group: I

Eligibility

Sex/Gender

All

Age

1 Days to 14 Days

Inclusion criteria

Inclusion criteria: Gestational age equal to or less than 37 weeks, The past time after birth equal to or less than 14 days, Patent ductus arteriosus

Exclusion criteria

Exclusion criteria: Infectious disease, Hyperbilirubinemia needing transfusion, Active necrotizing enterocolitis or intestinal perforation, Liver function disorder, Any hemorrhagic disorder, Retinopathy, Bronchopulmonary dysplasia, Platelet deficiency

Design outcomes

Primary

Measure	Time frame
The occlusion of patent ductus arteriosus. Timepoint: Three days after that. Method of measurement: Through echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mayam Zeinali

Hamedan University of Medical Sciences

parisazeinali@ymail.com+98 81 3828 3939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026